A Phase 3, Randomized, Active-Controlled, Double-Blind Trial of the Safety, Tolerability, and Immunologic Non-Inferiority of a 13-Valent Pneumococcal Conjugate Vaccine Compared to a 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Germany

Trial Profile

A Phase 3, Randomized, Active-Controlled, Double-Blind Trial of the Safety, Tolerability, and Immunologic Non-Inferiority of a 13-Valent Pneumococcal Conjugate Vaccine Compared to a 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Germany

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2012

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Otitis media; Pertussis; Pneumococcal infections; Pneumonia; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Most Recent Events

    • 22 Jun 2011 Results published in Vaccine.
    • 29 Oct 2009 Results were presented at IDSA 2009.
    • 27 Oct 2008 Study results have been reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top